Bristol Myers Squibb said it will use AI with Faro Health to streamline clinical trial protocol development using structured design tools. Under the multiyear agreement, Faro’s technology converts narrative protocol elements—such as objectives, endpoints, and schedules—into structured digital assets that AI agents can then draft and validate with traceability. BMS positioned the move as part of a shift away from document-only workflows, citing built-in alignment with industry standards such as the Tufts Center framework. Faro said it will also support simulations of patient and site burden and operational assessments. The partnership expands BMS’s push to modernize clinical development operations and reduce protocol build time, while maintaining human oversight over AI-generated outputs.